Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful ActivityValsamo Anagnostou, Patrick M. Forde, Deborah Collyar et al.|Clinical Cancer Research|2017Cited by 181
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckKevin J. Harrington, Robert I. Haddad, Robert L. Ferris et al.|JAMA Oncology|2023Cited by 73
Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targetsCoralea Kappel, Srikala S. Sridhar, Di Jiang et al.|Clinical Genitourinary Cancer|2022Cited by 3